Evaluation of WO2013117503 and WO2013117504: the use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.24, Iss.6, 2014-06, pp. : 719-722

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Novel 1,5-naphthyridine PI3Kδ inhibitors, an evaluation of WO2011075628

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 11, 2011-11 ,pp. : 1805-1810

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2012032067 and WO2012055846: two selective PI3Kδ inhibitors, which is GSK-2269557?

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 8, 2012-08 ,pp. : 965-970

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 8, 2012-08 ,pp. : 971-976

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2012003387, Gilead's ASK1 inhibitors

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 4, 2012-04 ,pp. : 455-459

Informa Healthcare

Access to resources Recommend Favorite

5-Lipoxygenase inhibitors: a patent evaluation (WO2011161615)

By Buscató Estel.la Proschak Ewgenij

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 7, 2012-07 ,pp. : 843-846

Informa Healthcare

Access to resources Recommend Favorite